These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 2968759

  • 1. Treatment of locally advanced prostatic carcinoma with LHRH analogues: cytological, DNA-cytophotometrical, and clinical results.
    Borgmann V, al-Abadi H, Nagel R.
    Am J Clin Oncol; 1988; 11 Suppl 1():S19-28. PubMed ID: 2968759
    [Abstract] [Full Text] [Related]

  • 2. Results of a Dutch trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer and results of EORTC studies in prostatic cancer.
    Debruyne FM.
    Am J Clin Oncol; 1988; 11 Suppl 1():S33-5. PubMed ID: 2968760
    [Abstract] [Full Text] [Related]

  • 3. [1st clinical results of the treatment of locally advanced prostatic cancer with a powerful LH-RH analog: buserelin acetate].
    Nagel R, Borgmann V, Al-Abadi H, Schmidt-Gollwitzer M.
    J Urol (Paris); 1983; 89(9):669-76. PubMed ID: 6425419
    [Abstract] [Full Text] [Related]

  • 4. The prognostic significance of ploidy and DNA-heterogeneity in the primary diagnosis and monitoring of patients with locally advanced prostatic carcinoma.
    Nagel R, al Abadi H.
    Scand J Urol Nephrol Suppl; 1991; 138():83-92. PubMed ID: 1785025
    [Abstract] [Full Text] [Related]

  • 5. Endocrine and clinical evaluation of 107 patients with advanced prostatic carcinoma under long-term pernasal buserelin or intramuscular decapeptyl depot treatment.
    Jacobi GH, Wenderoth UK, Ehrenthal W, von Wallenberg H, Spindler HW, Hohenfellner R.
    Am J Clin Oncol; 1988; 11 Suppl 1():S36-43. PubMed ID: 2968761
    [Abstract] [Full Text] [Related]

  • 6. [Chemical castration using a depot LHRH-agonist as a palliative therapy concept in prostatic carcinoma--clinical, endocrinological and experimental studies].
    Kuber W, Treu T, Kratzik C, Girsch E, Zeillinger R, Spona J.
    Wien Klin Wochenschr; 1990 Nov 09; 102(21):640-7. PubMed ID: 2148044
    [Abstract] [Full Text] [Related]

  • 7. PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients.
    Oosterlinck W, Mattelaer J, Casselman J, Van Velthoven R, Derde MP, Kaufman L.
    Acta Urol Belg; 1997 Oct 09; 65(3):63-71. PubMed ID: 9421938
    [Abstract] [Full Text] [Related]

  • 8. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
    Moreau JP, Delavault P, Blumberg J.
    Clin Ther; 2006 Oct 09; 28(10):1485-508. PubMed ID: 17157109
    [Abstract] [Full Text] [Related]

  • 9. Use of gonadotropin-releasing hormone analogue in advanced prostatic cancer: 3 years clinical experience.
    Matzkin H, Greenstein A, Kaver I, Braf Z.
    Isr J Med Sci; 1989 Jul 09; 25(7):388-92. PubMed ID: 2474522
    [Abstract] [Full Text] [Related]

  • 10. Duration of testosterone suppression after a 9.45 mg implant of the GnRH-analogue buserelin in patients with localised carcinoma of the prostate a 12-month follow-up study.
    Pettersson B, Varenhorst E, Petas A, Sandow J.
    Eur Urol; 2006 Sep 09; 50(3):483-9. PubMed ID: 16626856
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: a retrospective multicenter study.
    Ueno S, Namiki M, Fukagai T, Ehara H, Usami M, Akaza H.
    Int J Urol; 2006 Dec 09; 13(12):1494-500. PubMed ID: 17118024
    [Abstract] [Full Text] [Related]

  • 12. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen.
    Labrie F, Dupont A, Belanger A, Cusan L, Lacourciere Y, Monfette G, Laberge JG, Emond JP, Fazekas AT, Raynaud JP, Husson JM.
    Clin Invest Med; 1982 Dec 09; 5(4):267-75. PubMed ID: 6819101
    [Abstract] [Full Text] [Related]

  • 13. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
    Labrie F, Dupont A, Giguère M, Borsanyi JP, Lacourciere Y, Bélanger A, Lachance R, Emond J, Monfette G.
    Prog Clin Biol Res; 1988 Dec 09; 260():41-62. PubMed ID: 3283766
    [Abstract] [Full Text] [Related]

  • 14. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
    Calais da Silva FE, Bono AV, Whelan P, Brausi M, Marques Queimadelos A, Martin JA, Kirkali Z, Calais da Silva FM, Robertson C.
    Eur Urol; 2009 Jun 09; 55(6):1269-77. PubMed ID: 19249153
    [Abstract] [Full Text] [Related]

  • 15. [Therapy of prostatic cancer with cyproterone acetate].
    Maier U.
    Wien Klin Wochenschr; 1988 Jan 08; 100(1):16-9. PubMed ID: 2964127
    [Abstract] [Full Text] [Related]

  • 16. Treatment of prostatic cancer with LH-RH analogues.
    Borgmann V, Nagel R, Al-Abadi H, Schmidt-Gollwitzer M.
    Prostate; 1983 Jan 08; 4(6):553-68. PubMed ID: 6415628
    [Abstract] [Full Text] [Related]

  • 17. [Clinical studies in prostatic carcinoma].
    Kumanov Kh, Tsvetkov M.
    Khirurgiia (Sofiia); 1993 Jan 08; 46(5):6-8. PubMed ID: 7983831
    [Abstract] [Full Text] [Related]

  • 18. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
    Labrie F, Dupont A, Belanger A, Lefebvre FA, Raynaud JP.
    J Pharmacol; 1983 Jan 08; 14 Suppl 3():117-35. PubMed ID: 6423907
    [Abstract] [Full Text] [Related]

  • 19. A long term follow-up of patients with advanced prostatic cancer treated with buserelin.
    Waxman JH, Hendry WF, Whitfield HN, Oliver RT.
    Prog Clin Biol Res; 1985 Jan 08; 185A():271-7. PubMed ID: 3929266
    [Abstract] [Full Text] [Related]

  • 20. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas.
    Stege R, Grande M, Carlström K, Tribukait B, Pousette A.
    Clin Cancer Res; 2000 Jan 08; 6(1):160-5. PubMed ID: 10656445
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.